Accessibility Menu
ARS Pharmaceuticals Stock Quote

ARS Pharmaceuticals (NASDAQ: SPRY)

$9.12
(-5.5%)
-0.54
Price as of October 24, 2025, 3:58 p.m. ET

KEY DATA POINTS

Current Price
$9.12
Daily Change
(-5.5%) $0.54
Day's Range
$9.08 - $9.72
Previous Close
$9.12
Open
$9.63
Beta
1.06
Volume
67,292
Average Volume
2,465,459
Market Cap
953.7M
Market Cap / Employee
$9.65M
52wk Range
$9.08 - $18.90
Revenue
-
Gross Margin
0.94%
Dividend Yield
N/A
EPS
-$0.49
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

ARS Pharmaceuticals Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
SPRY-40.84%N/AN/A+59%
S&P+16.9%+95.99%+14.39%+81%

ARS Pharmaceuticals Company Info

ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. Its product includes Epinephrine Nasal Spray. The company was founded by Richard Lowenthal, Robert Bell, and Sarina Tanimoto on August 5, 2015 and is headquartered in San Diego, CA.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$15.72M3043.4%
Gross Profit$10.73M2126.8%
Gross Margin68.29%-28.1%
Market Cap$1.71B107.8%
Market Cap / Employee$10.71M0.0%
Employees160515.4%
Net Income-$44.88M-258.6%
EBITDA-$47.34M-208.9%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$51.54M40.7%
Accounts Receivable$25.13M0.0%
Inventory8.70.0%

Liabilities

Q2 2025YOY Change
Long Term Debt$1.07M0.0%
Short Term Debt$0.59M268.1%

Ratios

Q2 2025YOY Change
Return On Assets-17.94%0.7%
Return On Invested Capital-16.41%-209.7%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$39.64M-441.8%
Operating Free Cash Flow-$39.59M-443.9%

Valuation

MetricQ4 2024YoY Change
Price to Earnings137.55-
Price to Book6.535.104.807.48103.71%
Price to Sales547.8911.5912.7015.28-99.07%
Price to Tangible Book Value6.535.304.947.72110.36%
Price to Free Cash Flow TTM79.59-
Enterprise Value to EBITDA-55.3415.19-25.96-31.22-20.98%
Free Cash Flow Yield1.3%-
Return on Equity-22.4%3.3%-6.9%-23.6%21.85%
Total Debt$0.10M$0.04M$0.07M$1.66M938.13%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.